Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened Regimen for Drug-susceptible TB in Children
NCT06253715Phase 3Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jan 2025
- Primary completion
- Sep 2027
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 3 trial of rifapentine, moxifloxacin in Tuberculosis (TB), sponsored by Johns Hopkins University. Started Jan 2025; status: recruiting.
02
Drugs
rifapentinemoxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06253715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253715.